GRAPPA Psoriatic Arthritis Assessment and Treatment Guideline Summary - Guideline Central

Document Overview

Document Title
Psoriatic Arthritis Assessment and Treatment
Authoring Society

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Document Publication Date
Jun 27, 2022
Page Last Reviewed/Updated
May 6, 2026
Document Type
Guideline
Country of Publication
United States
Full Text Freely Available
Yes
Full Text Guideline
www.nature.com/articles/s41584-022-00798-0
Source Citation

Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol (2022). https://doi.org/10.1038/s41584-022-00798-0


Supplemental Implementation Resources


Document Scope, Criteria, and Use Cases

Document Objectives

Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have advanced considerably. This work reviews the literature since the previous recommendations (data published 2013–2020, including conference presentations between 2017 and 2020) and reports high-quality, evidence-based, domain-focused recommendations for medication selection in PsA developed by GRAPPA clinicians and patient research partners. The overarching principles for the management of adults with PsA were updated by consensus. Principles considering biosimilars and tapering of therapy were added, and the research agenda was revised. Literature searches covered treatments for the key domains of PsA: peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail psoriasis; additional searches were performed for PsA-related conditions (uveitis and inflammatory bowel disease) and comorbidities. Individual subcommittees used a GRADE-informed approach, taking into account the quality of evidence for therapies, to generate recommendations for each of these domains, which were incorporated into an overall schema. Choice of therapy for an individual should ideally address all disease domains active in that patient, supporting shared decision-making. As safety issues often affect potential therapeutic choices, additional consideration was given to relevant comorbidities. These GRAPPA treatment recommendations provide up-to-date, evidence-based guidance on PsA management for clinicians and people with PsA.

Scope
Assessment and Screening, Diagnosis, Management, Treatment
Keywords
GRACE, PASDAS, RAPID3, enthesis, peripheral arthritis, psoriasis, psoriatic arthritis, skin psoriasis
Target Patient Population
patients with Psoriasis and/or Psoriatic Arthritis
Inclusion Criteria
Male, Female, Adult, Older Adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resource
Data Supplement
Number of Source Documents
215
Literature Search Start Date
Tuesday, February 19, 2013
Literature Search End Date
Tuesday, November 10, 2020
Includes peer/external review process?
Yes
Includes public comment process?
No
Methodologist involvement?
Yes
Patient involvement?
No
Includes multi-disciplinary group?
Yes
Includes systematic review?
Yes
Grades quality of strength of evidence?
Yes
Grades quality of strength of recommendation?
Yes
Discloses funding source?
Yes
Discloses conflicts of interest?
Yes
Includes benefits/harms analysis with recommendations?
No
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.